RxDoctor Payments Data

James Lukas

Psychiatric/Mental Health · Cumberland, MDNPI 1083120687

Payments from drug & device makers

$4,748in general payments, 2019–2025

Across 219 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$773
  • Supernus Pharmaceuticals, Inc.$478
  • Corium, LLC$463
  • Neurocrine Biosciences, Inc.$384
  • Axsome Therapeutics, Inc.$364
  • plus $942 from 8 others

What the payments were for

  • Food & beverage$4,59297%
  • Education$1563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,748 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$37,060
Medicare patients
54
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate24$198,976
VraylarCariprazine Hcl65$94,983
Austedo XrDeutetrabenazine12$90,628
AuvelityDextromethorphan Hbr/Bupropion19$24,400
Aripiprazole37$9,845
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$1,604
Clomipramine Hcl13$1,225
Ramelteon20$1,180
Buspirone Hcl76$1,009
Divalproex Sodium33$977
Risperidone65$962
Lamotrigine92$859
Fluvoxamine Maleate21$702
Mirtazapine77$644
Bupropion XlBupropion Hcl39$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$384$198,97624 claims
AbbVieVraylar$1,345$94,98365 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$773$90,62812 claims
Axsome Therapeutics, Inc.Auvelity$364$24,40019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →